Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the completion of a clinical study with the company?s PaQ(? )Insulin Delivery Device. The study was designed to evaluate the ability of people with type 2 diabetes to use PaQ in replacing their multiple daily insulin injections required to control their blood sugar. Study endpoints included glycemic control, patient satisfaction and safety.
The study comprised three two-week periods: baseline, transition to PaQ, and PaQ treatment period. Professor Thomas Pieber and his team at the University Hospital Graz, Austria enrolled and completed the study in six months. CeQur expects to share initial results early next year.
PaQ is a discreet, wearable device that provides three days of consistent, basal insulin delivery along with easy, on-demand bolus insulin. The small device comprises a disposable insulin infuser reservoir attached to a reusable insulin monitor. PaQ is simple to use, making it easy to train patients to start and stay on therapy.
http://www.redorbit.com/news/health...ng-ability-of-simple-insulin-delivery-device/
The study comprised three two-week periods: baseline, transition to PaQ, and PaQ treatment period. Professor Thomas Pieber and his team at the University Hospital Graz, Austria enrolled and completed the study in six months. CeQur expects to share initial results early next year.
PaQ is a discreet, wearable device that provides three days of consistent, basal insulin delivery along with easy, on-demand bolus insulin. The small device comprises a disposable insulin infuser reservoir attached to a reusable insulin monitor. PaQ is simple to use, making it easy to train patients to start and stay on therapy.
http://www.redorbit.com/news/health...ng-ability-of-simple-insulin-delivery-device/